Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy
The use of monoclonal antibodies that block immunologic checkpoints, which mediate adaptive immune resistance, has revolutionized the treatment of metastatic melanoma patients. Specifically, targeting single immune suppressive molecules such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4), or programmed cell death protein 1 (PD-1) expressed on T cells or its primary ligand, programmed cell death ligand 1 (PD-L1), resulted in pronounced clinical benefit for a subset of melanoma patients. Although single-agent immune checkpoint inhibitor therapy has demonstrated promising clinical activity in metastatic melanoma patients, there is still a significant proportion of patients who show primary resistance to these therapies. Increased clinical efficacy was reported in phase II and III randomized studies by co-targeting CTLA-4 and PD-1 in the treatment of advanced melanoma, indicating the existence of multiple non-redundant immunosuppressive pathways in the tumor microenvironment. Nevertheless, only 50% of patients responded to combined anti-CTLA-4 and anti-PD-1 treatment. Additionally, the combination regimen was associated with severe toxicity in >50–60% of patients. In this review we summarize the rationale for new checkpoint inhibitor combinations in melanoma therapy and discuss how biologic-driven stratification enables the design of optimal combination therapies tailored to target different tumor microenvironments.
KeywordsMelanoma Overall Survival Ipilimumab Vemurafenib Chimeric Antigen Receptor
Compliance with Ethical Standards
This work was supported by Fondazione Oncologica Bergamasca (MM); Ministero dell’Istruzione, dell’Università e della Ricerca, Rome (MiUR) (PRIN 2015HAJH8E) (DM), and Fondazione Ente Cassa di Risparmio di Firenze (DM).
Conflict of interest
Dr. Mandala has received honoraria from Novartis, GSK, BMS, MSD, and Roche; personal fees for speakers bureau participation from Novartis, GSK, Roche, and BMS; personal fees for advisory board participation from Novartis, Amgen, MSD, and BMS; and research funding from Roche. Dr. Massi has received personal fees for speakers bureau participation from Novartis, GSK, Roche, Menarini Diagnostics, and BMS; and personal fees for advisory board participation from MSD. Dr. Tondini and Dr. Merelli declare no conflicts of interest.
- 13.Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff JR, Lawarence DP, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17(7):943–55.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol. 2013;31(Suppl; Abstract 9010). ASCO Annual Meeting 2013.Google Scholar
- 15.Ribas A, Butler M, Lutzky J, et al. Phase 1 study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol. 2015;33(Suppl. Abstract 3003). ASCO Annual Meeting 2015.Google Scholar
- 21.Li B, Van Roey M, Wang C, Chen THT, Korman A, Jooss K. Anti-programmed death-1 synergizes with granulocyte macrophage colony stimulating factor secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res. 2009;15:1632–4.Google Scholar
- 26.Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558–68.CrossRefPubMedGoogle Scholar
- 27.Hodi FS, Postow MA; Chesney JA, Pavlick AC, Robert C, Grossmann KF, et al. Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). J Clin Oncol. 2016;34(Suppl, Abstract 9518). ASCO Annual Meeting 2016.Google Scholar
- 29.Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2016;34 (Suppl; Abstract 9505). ASCO Annual Meeting 2016.Google Scholar
- 56.Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaiket A, et al. al. Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors. J Clin Oncol. 2016;34 (Suppl; Abstract 3002). ASCO Annual Meeting 2016.Google Scholar
- 58.Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, et al. Pembrolizumab (pembro) plus ipilimumab (IPI) for advanced melanoma: results of the KEYNOTE-029 expansion cohort. J Clin Oncol. 2016;34(Suppl; Abstract 9506). ASCO Annual Meeting 2016.Google Scholar
- 60.Bowen RC, Meek S, Williams M, Grossmann KF, Andtbacka RHI, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Holmen SL, Van Brocklin MW, Khong HT. A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma. J Clin Oncol. 2015;33(15 Suppl.):1.Google Scholar
- 63.Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116.Google Scholar
- 64.Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 20;515(7528):568–71.Google Scholar
- 65.Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, Bieche I, Baroni G, Cattaneo L, Xue G, Mandalà M. Baseline ß-catenin, PD-L1 expression and tumor-infiltrating lymphocytes predict response and poor prognosis in BRAFi-treated melanoma patients. Eur J Cancer. 2017;78:70–81.CrossRefPubMedGoogle Scholar